Brokerages expect Myokardia Inc (NASDAQ:MYOK) to announce earnings of ($1.48) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Myokardia’s earnings. The highest EPS estimate is ($1.32) and the lowest is ($1.69). Myokardia reported earnings per share of ($1.34) in the same quarter last year, which would suggest a negative year over year growth rate of 10.4%. The company is scheduled to issue its next quarterly earnings results on Monday, November 2nd.
According to Zacks, analysts expect that Myokardia will report full year earnings of ($5.64) per share for the current fiscal year, with EPS estimates ranging from ($6.22) to ($5.09). For the next fiscal year, analysts anticipate that the firm will report earnings of ($5.99) per share, with EPS estimates ranging from ($7.02) to ($4.39). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Myokardia.
Myokardia (NASDAQ:MYOK) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.46) by $0.19.
In other news, Director Mary B. Cranston sold 21,629 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $96.60, for a total value of $2,089,361.40. Following the completion of the transaction, the director now directly owns 371 shares in the company, valued at $35,838.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Anastasios Gianakakos sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $93.98, for a total transaction of $469,900.00. Following the transaction, the chief executive officer now owns 22,346 shares in the company, valued at approximately $2,100,077.08. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by company insiders.
Several hedge funds have recently modified their holdings of the company. FMR LLC lifted its holdings in shares of Myokardia by 13.4% in the second quarter. FMR LLC now owns 7,919,327 shares of the biotechnology company’s stock valued at $765,166,000 after buying an additional 933,147 shares during the period. Vanguard Group Inc. raised its position in Myokardia by 13.2% in the second quarter. Vanguard Group Inc. now owns 4,564,674 shares of the biotechnology company’s stock worth $441,039,000 after acquiring an additional 532,583 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Myokardia by 48.9% in the 1st quarter. Janus Henderson Group PLC now owns 1,524,881 shares of the biotechnology company’s stock valued at $71,486,000 after acquiring an additional 500,462 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its position in shares of Myokardia by 103.2% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 704,000 shares of the biotechnology company’s stock valued at $68,020,000 after purchasing an additional 357,591 shares in the last quarter. Finally, Vivo Capital LLC acquired a new position in shares of Myokardia in the 1st quarter worth approximately $15,640,000.
MYOK stock traded up $3.39 during midday trading on Wednesday, reaching $130.43. The company had a trading volume of 543,179 shares, compared to its average volume of 530,912. The firm has a market capitalization of $6.91 billion, a PE ratio of -18.34 and a beta of 2.20. The stock has a 50 day moving average price of $104.16 and a 200 day moving average price of $84.88. Myokardia has a fifty-two week low of $42.65 and a fifty-two week high of $133.98.
Myokardia Company Profile
MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.
See Also: Why are trading ranges significant?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.